Search

Your search keyword '"Alfieri, Veronica"' showing total 15 results
Start Over Author "Alfieri, Veronica" Publisher european respiratory society
15 results on '"Alfieri, Veronica"'

3. Evaluation of CCL18 serum levels and genetic variant as prognostic biomarkers in SSc-ILD

Author

Stock, Carmel, primary, Kokosi, Maria, additional, Alfieri, Veronica, additional, Kouranos, Vasilios, additional, George, Peter, additional, Molyneaux, Philip, additional, Chua, Felix, additional, Seeliger, Benjamin, additional, Ong, Voon, additional, Abraham, David, additional, Witte, Torsten, additional, Denton, Christopher, additional, Prasse, Antje, additional, Wells, Athol, additional, and Renzoni, Elisabetta, additional

Published
2021
Full Text
View/download PDF

4. Comorbidities in sarcoidosis: a retrospective Italian study

Author

Aredano, Ilaria, primary, Burgazzi, Barbara, additional, Beneventi, Elena, additional, Goldoni, Matteo, additional, Alfieri, Veronica, additional, Aiello, Marina, additional, Agusta, Fabio, additional, Bertorelli, Giuseppina, additional, and Chetta, Alfredo Antonio, additional

Published
2020
Full Text
View/download PDF

5. Serum biomarkers in SSc-ILD: association with presence, severity and prognosis

Author

Stock, Carmel, primary, De Lauretis, Angelo, additional, Visca, Dina, additional, Daccord, Cecile, additional, Kokosi, Maria, additional, Alfieri, Veronica, additional, Kouranos, Vasilis, additional, Margaritopoulos, George, additional, George, Peter, additional, Molyneaux, Philip, additional, Chua, Felix, additional, Maher, Toby, additional, Ong, Voon, additional, Abraham, David, additional, Denton, Christopher, additional, Wells, Athol, additional, and Renzoni, Elizabetta, additional

Published
2019
Full Text
View/download PDF

8. Verification of genetic associations with Scleroderma associated Interstitial Lung Disease

Author

Stock, Carmel, primary, De Lauretis, Angelo, additional, Visca, Dina, additional, Daccord, Cecile, additional, Kokosi, Maria, additional, Alfieri, Veronica, additional, Kouranos, Vasilis, additional, Margaritopoulos, George, additional, George, Peter, additional, Molyneaux, Philip, additional, Chua, Felix, additional, Maher, Toby, additional, Abraham, David, additional, Denton, Christopher, additional, Ong, Voon, additional, Wells, Athol, additional, and Renzoni, Elizabetta, additional

Published
2019
Full Text
View/download PDF

9. Pulmonary function trends predict mortality in patients with hypersensitivity pneumonitis

Author

Boccabella, Cristina, primary, Macaluso, Claudio, additional, Kokosi, Maria, additional, Alfieri, Veronica, additional, Stock, Carmel, additional, Kouranos, Vasilis, additional, Margaritopoulos, George, additional, Mori, Letizia, additional, Barnett, Joseph, additional, Molyneaux, Philip, additional, George, Peter, additional, Chua, Felix, additional, Maher, Toby, additional, Desai, Sujal, additional, Jacob, Joseph, additional, Devaraj, Anand, additional, Wells, Athol, additional, and Renzoni, Elisabetta, additional

Published
2018
Full Text
View/download PDF

11. Serum KL-6 as a marker of disease progression in SSc-ILD

Author

Stock, Carmel, primary, Hoyles, Rachel, additional, D'Accord, Cecile, additional, Kokosi, Maria, additional, Alfieri, Veronica, additional, Campochiaro, Corrado, additional, Donovan, Jackie, additional, Mori, Letizia, additional, Maher, Toby M, additional, Kouranos, Vasilis, additional, Margaritopoulos, George, additional, George, Peter M, additional, Molyneaux, Philip L, additional, Chua, Felix, additional, Ong, Voon, additional, Denton, Christopher P, additional, Wells, Athol U, additional, and Renzoni, Elizabetta A, additional

Published
2018
Full Text
View/download PDF

13. Gastro-oesophageal dismotility measurements in scleroderma-associated interstitial lung disease: Correlation with respiratory and reflux symptoms

Author

De Lauretis, Angelo, primary, Visca, Dina, additional, Ward, Simon, additional, Clayman, Claudia, additional, Murray, Charles, additional, Voon, Ong, additional, Denton, Christopher, additional, Lindahl, Gisela, additional, Stock, Carmel, additional, Chetta, Alfredo, additional, Aiello, Marina, additional, Alfieri, Veronica, additional, Kreuter, Michael, additional, Wuyts, Wim, additional, Maher, Toby, additional, Wells, Athol U., additional, and Renzoni, Elisabetta, additional

Published
2015
Full Text
View/download PDF

14. Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease.

Author

Alfieri V, Crisafulli E, Visca D, Chong WH, Stock C, Mori L, de Lauretis A, Tsipouri V, Chua F, Kouranos V, Kokosi M, Hogben C, Molyneaux PL, George PM, Maher TM, Chetta AA, Sestini P, Wells AU, and Renzoni EA

Subjects
Fibrosis, Humans, Oxygen, Lung Diseases, Interstitial diagnosis
Abstract

Competing Interests: Conflict of interest: V. Alfieri has nothing to disclose. Conflict of interest: E. Crisafulli has nothing to disclose. Conflict of interest: D. Visca has nothing to disclose. Conflict of interest: W.H. Chong has nothing to disclose. Conflict of interest: C. Stock has nothing to disclose. Conflict of interest: L. Mori has nothing to disclose. Conflict of interest: A. de Lauretis has nothing to disclose. Conflict of interest: V. Tsipouri has nothing to disclose. Conflict of interest: F. Chua reports lecture fees and advisory board fees from Boehringer Ingelheim and from Roche, outside the submitted work. Conflict of interest: V. Kouranos has nothing to disclose. Conflict of interest: M. Kokosi has nothing to disclose. Conflict of interest: C. Hogben has nothing to disclose. Conflict of interest: P.L. Molyneaux has, via his institution, received industry-academic funding from Roche, Boehringer Ingelheim and Galapagos and has received speaker fees from Roche. Conflict of interest: P.M. George reports grants, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Roche, personal fees from Teva, outside the submitted work. Conflict of interest: T.M. Maher has, via his institution, received industry-academic funding from GlaxoSmithKline R&D and UCB and has received consultancy or speaker fees from Apellis, AstraZeneca, Bayer, Blade Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, GlaxoSmithKline R&D, Indalo, Novartis, Pliant, ProMetic, Respivnat, Roche, Samumed and UCB. Conflict of interest: A.A. Chetta has nothing to disclose. Conflict of interest: P. Sestini has nothing to disclose. Conflict of interest: A.U. Wells reports lecture fees and advisory board fees from Boeringher Ingelheim, Roche and Bayer, outside the submitted work. Conflict of interest: E.A. Renzoni reports lecture fees and advisory board fees from Boeringher Ingelheim and Roche, and lecture fees from Mundipharma, outside the submitted work.

Published
2020
Full Text
View/download PDF

15. Research highlights from the 2018 ERS International Congress: interstitial lung diseases.

Author

Alfaro TM, Moor CC, Alfieri V, Jeny F, Kreuter M, Wijsenbeek MS, Renzoni EA, Bargagli E, Nunes H, Spagnolo P, Bonella F, Molina-Molina M, Antoniou K, and Poletti V

Abstract

This article reviews a selection of the scientific presentations on interstitial lung disease (ILD)/diffuse parenchymal lung disease (DPLD) that were made at the 2018 European Respiratory Society (ERS) International Congress in Paris. A number of advances in the epidemiology, pathogenesis, diagnosis and treatment of these disorders were presented and discussed by clinicians and researchers. The research topics span over all four groups of ERS Assembly 12: Interstitial Lung Diseases (Group 12.01: Idiopathic interstitial pneumonias; Group 12.02: ILD/DPLD of known origin; Group 12.03: Sarcoidosis and other granulomatous ILD/DPLD; Group 12.04: Rare ILD/DPLD)., Competing Interests: Conflict of interest: T.M. Alfaro reports receiving travel support from Boehringer Ingelheim, Novartis, Astra, Menarini, Mundipharma, Zambon and Roche, and grants from Bayer, outside the submitted work. Conflict of interest: C.C. Moor has nothing to disclose. Conflict of interest: V. Alfieri has nothing to disclose. Conflict of interest: F. Jeny has nothing to disclose. Conflict of interest: M. Kreuter has nothing to disclose. Conflict of interest: M.S. Wijsenbeek reports grants and other support from Boehringer Ingelheim and Hoffman la Roche, and other support from Galapagos, outside the submitted work. Conflict of interest: E.A. Renzoni reports lecture and advisory board fees from Roche and Boehringer Ingelheim, and lecture fees from Mundipharma, outside the submitted work. Conflict of interest: E. Bargagli has nothing to disclose. Conflict of interest: H. Nunes reports consultancy and research support fees from Roche/Genentech and Boehringer Ingelheim, and grants and personal fees as a clinical trial investigator from Sanofi and Gilead. Conflict of interest: P. Spagnolo reports personal fees and nonfinancial support from Roche, Boehringer Ingelheim and Zambon, personal fees from PPM Services, Galapagos and Santhera Pharmaceuticals, outside the submitted work. Conflict of interest: F. Bonella reports personal fees and nonfinancial support from Roche Pharma, Boehringer Ingelheim and Fujrebio, outside the submitted work. Conflict of interest: M. Molina-Molina reports grants from Roche, Boehringer Ingelheim and grants from Esteve-Teijin Healthcare, and personal fees for specialised medical training from Chiesi, outside the submitted work. Conflict of interest: K. Antoniou has nothing to disclose. Conflict of interest: V. Poletti has nothing to disclose.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results